close menu

Latest cancer research...Your pension fund?

by Sable International | Jan 05, 2012
  • It doesn’t necessarily mean you need to invest in Bio-technology firms to fund your retirement. Instead, the goal here is to make you aware of some of the most important trends taking place in the bio-tech industry at the moment. These developments are hugely exciting and they are potentially transformative for society as we know it. But like many innovations they will have both positive and unintended negative consequences.
    auto-enrolment-now

    It doesn’t necessarily mean you need to invest in Bio-technology firms to fund your retirement. Instead, the goal here is to make you aware of some of the most important trends taking place in the bio-tech industry at the moment. These developments are hugely exciting and they are potentially transformative for society as we know it. But like many innovations they will have both positive and unintended negative consequences.

    As advisers we read a lot and quite widely at times. One of the best technology commentators out there is Pat Cox. He’s recently posted some very interesting facts on the latest developments in the biotech space. The most interesting of these focus on cancer treatment. Cancer treatment costs the US alone around $200 billion a year. So in developed nations this is one of the biggest problems faced by debt burdened governments who (quite rightly) see the demographic cards stacked against them. Cancer treatment success rates skyrocket when the disease is diagnosed early. If diagnosed late the treatment is hugely expensive and adds relatively little additional quality of life to the patient. In pure economic terms it’s a low return business which we fund because our humanity requires us to. However if diagnosed early cancer treatment success rates are quite high and the eventual cost falls considerably.

    Rafts of small bio-tech firms in the US are making considerable headway toward the goal of developing accurate, inexpensive and early diagnosis. The problem is that there has never been a way to test for all cancers. Each and every cancer (and there’s a long list of them) requires a separate diagnostic test. However now one of these firms has used gene mapping to create a very simple and inexpensive blood test to find genetic blood markers. Genetic code hacking has allowed this company to map over 40,000 gene sequences and it’s this vast database of research that allowed them to discover the fact that each cancer cell activates certain genes to secrete certain proteins. These proteins are relatively easy to test for. The result could be a simple device that costs £30 or £40 which is able to test for the presence of any type of cancer.

    So what does this mean? It means that anyone under the age of 45 is likely to see these and other medical discoveries offering them a much longer lifespan. It means the current accepted retirement age of 65 (which was conceived in the 30’s) is massively outdated. It means that you will more than likely live past 100. And as such you are going to need to be able to fund a far longer period of retirement. That problem has nothing to do with the future. That needs to be dealt with today. 

    For any questions on your financial planning please contact the author Mike Abbott at wealth@sableinternational.com.

    We are a professional services company that specialises in cross-border financial and immigration advice and solutions.

    Our teams in the UK, South Africa and Australia can ensure that when you decide to move overseas, invest offshore or expand your business internationally, you’ll do so with the backing of experienced local experts.

    • Man-on-a-rocket
      Are you a UK contractor? Maximise tax-efficiency by using your pension
      Sep 25, 2018  |  by Bill Monty
    • terraced-houses-in-london
      Are you a UK contractor? Here’s how to get your mortgage approved
      Sep 12, 2018  |  by Marlon Borez
    • property-feud
      The hidden dangers of not having a will in the UK
      Sep 07, 2018  |  by Sherron Alexander-Bedingfield
    • carrot-incentive-running-track
      UK pensions: Between a QROP and a hard place? Or is it a damp SIPP?
      Jun 21, 2018  |  by Niel Pretorius
    • piggy-bank-dollar
      What to do with your living annuity when you retire abroad
      Jun 11, 2018  |  by Niel Pretorius
    • house-london
      In the UK, mortgage inaction is pickpocketing thousands of homeowners
      Jun 07, 2018  |  by Bill Monty
    • Hand-currency-blue
      Saying goodbye to South Africa? Financial emigration can give you access to your RA before you turn 55
      Apr 13, 2018  |  by Niel Pretorius
    • Dubai_skyline
      Lessons learned on a trip to Dubai: South Africans take note
      Nov 10, 2017  |  by Mike Abbott
    • Piggy-banks-thinking
      Financial emigration: Transfer your retirement annuities out of South Africa
      Oct 20, 2017  |  by Niel Pretorius
    • row-of-houses-UK
      Bank of England overhauls mortgage affordability rates: Here’s what you need to know
      Oct 09, 2017  |  by Ian Henning
     
     

    South Africa

    Cape Town

    Regent Square
    Doncaster Road
    Kenilworth 7708 +27 (0) 21 657 2120

    Durban

    201 The Annex
    Ridgeside Office Park
    Umhlanga +27 (0) 31 536 8843

    United Kingdom

    London

    Castlewood House
    77/91 New Oxford Street
    WC1A 1DG +44 (0) 20 7759 7514

    Croydon

    5-7 Selsdon Road
    South Croydon
    CR2 6PU +44 (0) 20 7759 7581

    Australia

    Melbourne

    9 Yarra Street
    South Yarra
    VIC 3141 +613 (0) 8651 4500

    Sable International is a trading name of 1st Contact Money Limited (company number 07070528), registered in England and Wales. We are authorised and regulated by the Financial Conduct Authority in the UK (FCA no. 517570), the Financial Services Conduct Authority in South Africa (1st Contact Money [PTY] Ltd - FSP no. 41900) and hold an Australian Financial Services License issued by ASIC to deal in foreign exchange (1st Contact Group - AFS License number 335 126).

    This site uses cookies, read more or close this notice.